Archive for January 2026
Expanded Access of Kv7.2 Channel Activators
Kv7.2 Channel Activators In many cases, KCNQ2-DEE is caused by reduced Kv7.2 potassium channel activity. Because of this, therapeutics that boost the activity of these channels are likely to be…
Read MoreQ2 Quick Notes #08: Electronic Medical Records Help Show Trajectories of SCN8A-Related Disorders
Excerpt Researchers used existing medical records and data from the International SCN8A Registry to create individual profiles of people with SCN8A-related disorders. When combined, they revealed common patterns in how…
Read MoreQ2 Quick Note #07: Carbamazepine Improves Memory in Kcnq2 Mouse Model
Researchers treated mice carrying a Kcnq2 gene variant with a sodium channel-blocking drug called carbamazepine. Mice that received the drug had fewer seizures and performed better on memory-related tests compared…
Read MorePraxis EMERALD Clinical Trial
KCNQ2 Cure hosted a webinar for the KCNQ2 community featuring a discussion with Praxis Precision Medicines. Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for disorders…
Read More